MedTrace Logo

Nuclear Imaging of Human CSF Flow Using Ga-67 Citrate and In-111 DTPA

NCT00477503 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2012-08-01

No results posted yet for this study

Summary

* Primary Objective will be to evaluate the use of Ga-67 citrate as an alternative radiopharmaceutical for CSF imaging.
* Secondary Objective will be to evaluate the biodistribution, pharmacokinetics and radiation dosimetry of In 111 DTPA and gallium-67 after intrathecal injection during remission of leptomeningeal metastasis (LM) and during LM occurrence, remission and recurrence.

Conditions

Interventions

DRUG

Gallium-67 Citrate (Ga-67)

Group A: Ga-67 citrate injection alone, in the baseline study. Group B: Ga-67 and In 111 DTPA injection in the baseline study. Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

DRUG

In-111 DTPA (In-111 pentetate)

Group B: Ga-67 and In 111 DTPA injection in the baseline study. Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Franklin C Wong, M.D. · M.D. Anderson Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00477503 on ClinicalTrials.gov